William D Leslie1,2, Mark Bryanton3, Andrew Goertzen3, Piotr Slomka4. 1. Department of Radiology, University of Manitoba, C5121-409 Tache Ave, Winnipeg, MB, R2H 2A6, Canada. bleslie@sbgh.mb.ca. 2. Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. bleslie@sbgh.mb.ca. 3. Department of Radiology, University of Manitoba, C5121-409 Tache Ave, Winnipeg, MB, R2H 2A6, Canada. 4. Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Abstract
BACKGROUND: We developed CRAX2MACE, a new tool derived from clinical and SPECT myocardial perfusion imaging (MPI) variables, to predict 2-year probability of major adverse cardiac event (MACE) comprising death, hospitalized acute myocardial infarction or coronary revascularization. METHODS: Consecutive individuals with SPECT MPI 2001-2008 had two-year MACE determined from population-based health services data. CRAX2MACE included age, sex, diabetes, recent cardiac hospitalization, pharmacologic stress, stress total perfusion deficit (TPD), ischemic (stress-rest) TPD, left ventricular ejection fraction and transient ischemic dilation ratio. Two-year event rates were classified as low (< 5%), moderate (5.0-9.9%), high (10-19.9%) and very high (20% or greater). RESULTS: The study population comprised 3896 individuals for the development and 1946 for the validation subgroups with subsequent MACE in 589 (15.1%) and 272 (14.0%), respectively. CRAX2MACE, derived from the development subgroups, accurately stratified MACE risk in the validation subgroup (area under the receiver operating characteristics curve 0.79) with stepwise increase in the observed event rate with increasing predicted risk category (low, 2.3%; moderate, 5.5%; high, 18.8%; very high 33.2%; P-trend < 0.001). CONCLUSIONS: A simple tool based upon clinical risk factors and MPI variables predicts 2-year cardiac events. Risk stratification between the low and very high groups was greater than tenfold.
BACKGROUND: We developed CRAX2MACE, a new tool derived from clinical and SPECT myocardial perfusion imaging (MPI) variables, to predict 2-year probability of major adverse cardiac event (MACE) comprising death, hospitalized acute myocardial infarction or coronary revascularization. METHODS: Consecutive individuals with SPECT MPI 2001-2008 had two-year MACE determined from population-based health services data. CRAX2MACE included age, sex, diabetes, recent cardiac hospitalization, pharmacologic stress, stress total perfusion deficit (TPD), ischemic (stress-rest) TPD, left ventricular ejection fraction and transient ischemic dilation ratio. Two-year event rates were classified as low (< 5%), moderate (5.0-9.9%), high (10-19.9%) and very high (20% or greater). RESULTS: The study population comprised 3896 individuals for the development and 1946 for the validation subgroups with subsequent MACE in 589 (15.1%) and 272 (14.0%), respectively. CRAX2MACE, derived from the development subgroups, accurately stratified MACE risk in the validation subgroup (area under the receiver operating characteristics curve 0.79) with stepwise increase in the observed event rate with increasing predicted risk category (low, 2.3%; moderate, 5.5%; high, 18.8%; very high 33.2%; P-trend < 0.001). CONCLUSIONS: A simple tool based upon clinical risk factors and MPI variables predicts 2-year cardiac events. Risk stratification between the low and very high groups was greater than tenfold.
Authors: Tali Sharir; Xingping Kang; Guido Germano; Jeroen J Bax; Leslee J Shaw; Heidi Gransar; Ishac Cohen; Sean W Hayes; John D Friedman; Daniel S Berman Journal: J Nucl Cardiol Date: 2006-07 Impact factor: 5.952
Authors: X Kang; D S Berman; H C Lewin; I Cohen; J D Friedman; G Germano; R Hachamovitch; L J Shaw Journal: Am Heart J Date: 1999-12 Impact factor: 4.749
Authors: T Sharir; G Germano; P B Waechter; P B Kavanagh; J S Areeda; J Gerlach; X Kang; H C Lewin; D S Berman Journal: J Nucl Med Date: 2000-04 Impact factor: 10.057
Authors: Salvador Borges-Neto; Linda K Shaw; Robert H Tuttle; John H Alexander; William T Smith; Marianna Chambless; R Edward Coleman; Robert A Harrington; Robert M Califf Journal: Am J Cardiol Date: 2005-01-15 Impact factor: 2.778
Authors: D S Berman; X Kang; K F Van Train; H C Lewin; I Cohen; J Areeda; J D Friedman; G Germano; L J Shaw; R Hachamovitch Journal: J Am Coll Cardiol Date: 1998-12 Impact factor: 24.094
Authors: David M Kent; Jason Nelson; Issa J Dahabreh; Peter M Rothwell; Douglas G Altman; Rodney A Hayward Journal: Int J Epidemiol Date: 2016-12-01 Impact factor: 7.196
Authors: Waseem Hijazi; Willam Leslie; Neil Filipchuk; Ryan Choo; Stephen Wilton; Matthew James; Piotr J Slomka; Robert J H Miller Journal: J Nucl Cardiol Date: 2022-04-13 Impact factor: 3.872